Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gastrodin is a natural small molecule and the main bioactive component of the traditional Chinese medicinal herb Gastrodia elata (Tianma). Chemically, it is the glucoside of gastrodigenin (4-hydroxybenzyl alcohol). Gastrodin exerts significant pharmacological effects on the central nervous system, including sedation, improvement of sleep quality, neuroprotection, and analgesia. It has demonstrated efficacy in treating neurological disorders such as migraine, epilepsy, cognitive impairment, emotional disorders (such as anxiety and depression), neurodegenerative diseases (including Alzheimer's disease), and neurasthenia. Additional pharmacological activities include anti-inflammatory, antioxidant, vascular protective effects; blood sugar lowering; lipid regulation; analgesic; anticancer; and antiviral properties. Mechanistically, gastrodin modulates multiple signaling pathways such as Nrf2/ARE (antioxidant response), NF-κB (anti-inflammatory), PI3K/AKT/mTOR (cell survival/neuroprotection), AMPK (metabolic regulation), and may influence neurotransmitter systems including serotoninergic pathways. Gastrodin can be extracted from G. elata or synthesized chemically or via biosynthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gastrodin.